Allon granted US patent for composition of matter

14-Jun-2007 - Allon Therapeutics Inc. announced that it has been granted a US patent covering additional composition of matter for the products in the ADNP platform, which broadens the intellectual property of Allon's patent portfolio. Gordon McCauley, President and CEO of Allon, said these claims ...

Better Insight into Brain Anatomical Structures

Manganese oxide nanoparticles as contrast agents for brain magnetic resonance imaging

31-May-2007 - Magnetic resonance imaging is a very effective method for revealing anatomical details of soft tissues. Contrast agents can help to make these images even clearer and allow physiological processes to be followed in real time. Conventional gadolinium complexes currently used as MRI contrast agent ...

Study Reveals Process Linking Disordered Protein Folding and Binding

New Insights May Prove Useful In Future Protein Studies and Drug Development

30-May-2007 - A group of scientists at The Scripps Research Institute and the Skaggs Institute for Chemical Biology have uncovered one of the processes by which disordered or unstructured proteins become bound to specific cellular sites. The findings offer valuable insights into how proteins carry out their ...

Roche and Siena Biotech enter Research Collaboration Agreement in Neurodegenerative diseases

22-May-2007 - Siena Biotech S.p.A., announced that they have entered into a Research and Collaboration Agreement with Roche to perform joint research activities targeted towards treatment of selected neurodegenerative diseases. "This Collaboration Agreement with Roche is an excellent example of our commitment ...

$4 Trillion in Cost Savings to U.S. From New Disease-Modifying Alzheimer's Treatments

18-May-2007 - Myriad Genetics, Inc. reported that a new study has estimated the potential savings to the United States healthcare system, from a disease-modifying Alzheimer's drug, at up to $4.0 trillion. These savings would be for new cases arising between 2010, when the first such drug is estimated by the ...

Transition Therapeutics Completes Tender Offer for CNS-Focused NeuroMedix Inc.

14-May-2007 - Transition Therapeutics Inc. and NeuroMedix Inc. announced the successful completion of Transition's tender offer for the outstanding shares of NeuroMedix, a central nervous system ("CNS") focused biotechnology company. According to the company, NeuroMedix's lead compound, Minozac, has the key ...

Allon Therapeutics confirms oral bioavailability of CNS drug AL-309

26-Apr-2007 - Allon Therapeutics Inc. released new data confirming that the Company's product AL-309 has robust oral bioavailability in preclinical studies. This new data also shows that AL-309 enters the brain and that effective concentrations can be detected for extended periods of time. This information ...

New Study Confirms Innovative Therapies Will Have Minimal Impact on Healthcare Costs

12-Apr-2007 - The widening use of new, innovative biopharmaceutical treatments for diseases, such as cancer, multiple sclerosis and heart disease, will have a limited impact on healthcare costs for private healthcare payers over the next several years, according to an independent study released by the ...

FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005

10-Apr-2007 - Transition Therapeutics Inc. announced that the United States Food and Drug Administration has granted Fast Track designation to investigational drug candidate AZD-103/ELND005, being developed in collaboration with Elan Corporation, plc. for the treatment of Alzheimer's disease. AZD-103/ELND005 ...

Transition Therapeutics Inc. Builds on Its CNS Franchise with the Acquisition of NeuroMedix Inc.

23-Mar-2007 - Transition Therapeutics Inc. announced that it has signed an agreement to offer to purchase all of the outstanding shares of NeuroMedix Inc, a central nervous system ("CNS") focused biopharmaceutical company. NeuroMedix is developing a series of compounds that have been shown to improve cognitive ...